FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person [*] Kanter Stacy J.					2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [APLT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Kaller Stacy J.														Direc	ctor		10% O	wner	
(Last)	(F	(First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023								er (give title v)		Other (specify below)		
C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicabl Line)					
545 FIF III AVENUE, 5011E 1400														Form filed by One Reporting Person					
(Street) NEW YORK NY 10017														Form filed by More than One Reporting Person					
		1 1	0017		Dulo 10hE 1(a) Transaction Indication														
					Rui	Rule 10b5-1(c) Transaction Indication													
(City)	(S	tate) (Z	Zip)				nis box to indi ne affirmative								truction or wr	itten p	plan that is in	tended to	
		Table	I - No	n-Deriva	tive S	Secur	ities Acq	uired,	Dis	posed of	f, c	or Ben	eficia	ly Owr	ned				
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/					/Year) if any		tion Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)					icially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount		(A) or (D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 06/06/20						123		Α		20,000 ⁽¹⁾		Α	\$0.00	3	33,000		D		
		Tab	ole II -	Derivati (e.g., pu			ies Acqu varrants,							/ Owne	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any			ansaction Number ode (Instr. of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		f D S g (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Naturo of Indirec Beneficia Ownershi (Instr. 4)	

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on each of September 6, 2023, December 6, 2023, March 6, 2024 and the date which is the earlier of June 6, 2024 and the 2024 annual stockholder meeting, subject to the Reporting Person continuing to provide services through each such date.

(A)

(D)

v

Date

Exercisable

Expiration

Date

Remarks:

<u>/s/ Shoshana Shendelman, as</u> <u>attorney-in-fact</u>

Amount or Number of Shares

Title

<u>06/08/2023</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5